Protein delivery using engineered virus-like particles

Protein delivery using engineered virus-like particles.

Over the years, researchers have developed several methods to deliver macromolecules into the cytosol and nucleus of living cells. However, there are limitations to all of these methods. The problems include (i) inefficient uptake, (ii) endosomal entrapment, (iii) delivery that is restricted to certain cell types, and (iv) damage to cells in the delivery process. Retroviral vectors are often us...

Virus-like particles as drug delivery vectors.

Virus-like particles (VLPs) assemble spontaneously during the viral cycle or in heterologous systems during expression of viral structural protein. Depending on the complexity of the VLPs, they can be obtained by expression in prokaryotic or eukaryotic expression system from the suitable recombinant vectors, or formed in cell-free conditions. Moreover, they can be built from proteins of a singl...

Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery

Most drug therapies distribute the agents throughout the entire body, even though the drugs are typically only needed at specific tissues. This often limits dosage and causes discomfort and harmful side-effects. Significant research has examined nanoparticles (NPs) for use as targeted delivery vehicles for therapeutic cargo, however, major clinical success has been limited. Current work focuses...

expression of cucumber mosaic virus coat protein and its assembly into virus like particles

background cucumber mosaic virus (cmv) has isometric particles with a diameter of about 28–29 nm. a useful method to recognize regions from mutagenesis in the coat protein (cp) gene are important for particle assembly and the expression of viral in cp expression systems like bacteria such as e.coli or yeast as well as their assembly into virus-like particles (vlp). objectives in this paper, we ...

Avian lymphoid leukosis: Virus-like particles in kidney Cells